deltatrials
Completed PHASE2/PHASE3 NCT00000135

Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)

Monoclonal Antibody CMV Retinitis Trial (MACRT)

Sponsor: Johns Hopkins Bloomberg School of Public Health

Conditions Cytomegalovirus Retinitis HIV Infections
Interventions MSL-109 Placebo
Updated 6 times since 2017 Last updated: Oct 14, 2015 Started: Sep 30, 1995 Primary completion: Aug 31, 1996 Completion: Aug 31, 1996

This PHASE2/PHASE3 trial investigates Cytomegalovirus Retinitis and HIV Infections and is currently completed. Johns Hopkins Bloomberg School of Public Health leads this study, which shows 6 recorded versions since 1995 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Sep 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Johns Hopkins Bloomberg School of Public Health
Data source: Johns Hopkins Bloomberg School of Public Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.